Elimination of cervical cancer depends on HPV vaccination and primary HPV screening
Menée en Finlande à partir des données de 2 essais randomisés de phase III portant sur des échantillons de sérum de jeunes filles vaccinées contre le papillomavirus humain, cette étude analyse la persistance des anticorps neutralisants jusqu'à 12 ans après le vaccin, qu'il soit bivalent ou quadrivalent
WHO has put forth a challenge for the next century to reduce the incidence of cervical cancer globally to fewer than four cases per 100 000 women, a level equated with elimination. Globally, the range of cervical cancer incidence is far from the WHO goal, with one of the lowest human development index (HDI) countries Eswatini at 75·3 cases per 100 000 women, and the higher HDI regions at 10·4 cases per 100 000 women. Historically, cervical cancer incidence has steadily decreased because of opportunistic and organised screening programmes. Between 1990 and 1995, Finland reached a cervical cancer incidence of fewer than four cases per 100 000 women through organised screening; nonetheless, a subsequent decrease in participation in screening among women aged 30–35 years led to an increased incidence within a 5-year timeframe. Cytology as a primary screen has been replaced by primary human papillomavirus (HPV) cervical screening, which has a 70% greater protection against invasive cervical cancer than cytology.